Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 8 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
8 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 1 Annual Reports

globalSalesInformation
1 US Medicaid Prescriptions
1 Annual Reports

MARKET PLACE

1 FDF Dossiers

marketPlace
1 FDF Dossiers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

1,433,409

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Lumacaftor / ivacaftor, Lumacaftor and ivacaftor, Lumacaftor and ivacaftor tablet, Schembl19410545, Vx 700-vx 809 combination, Vx 809-vx 770 combination

Molecular Formula

C₄₈H₄₆F₂N₄O₈

Molecular Weight

844.9 g/mol

InChI Key

YQCGOSZYHRVOFW-UHFFFAOYSA-N

1 2D Structure

Orkambi

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide;3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid

2.1.2 InChI

InChI=1S/C24H18F2N2O5.C24H28N2O3/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17;1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31);7-13,27H,1-6H3,(H,25,28)(H,26,29)

2.1.3 InChI Key

YQCGOSZYHRVOFW-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O.CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Ivacaftor - Lumacaftor

2. Ivacaftor, Lumacaftor Drug Combination

3. Lumacaftor, Ivacaftor Drug Combination

2.2.2 Depositor-Supplied Synonyms

1. Lumacaftor / Ivacaftor

2. Lumacaftor And Ivacaftor

3. Lumacaftor And Ivacaftor Tablet

4. Schembl19410545

5. Vx 700-vx 809 Combination

6. Vx 809-vx 770 Combination

7. Ivacaftor Mixture With Lumacaftor

8. Lumacaftor, Ivacaftor Drug Combination

9. S900006790

10. 1815566-23-4

2.3 Create Date

2013-06-10

3 Chemical and Physical Properties

Molecular Formula	C₄₈H₄₆F₂N₄O₈
Molecular Weight	844.9 g/mol
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	9
Exact Mass	844.32837076 g/mol
Monoisotopic Mass	844.32837076 g/mol
Topological Polar Surface Area	176 Å²
Heavy Atom Count	62
Formal Charge	0
Complexity	1450
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 1
Drug Name	ORKAMBI
Active Ingredient	IVACAFTOR; LUMACAFTOR
Company	VERTEX PHARMS INC (Application Number: N206038. Patents: 7495103, 7973038, 8324242, 8410274, 8507534, 8653103, 8716338, 8741933, 8754224, 8846718, 8993600, 9150552, 9192606, 9216969, 9670163, 9931334)

4.2 Drug Indication

Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.

Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene.

5 Pharmacology and Biochemistry

5.1 FDA Pharmacological Classification

5.1.1 Pharmacological Classes

Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]; Cytochrome P450 2B6 Inducers [MoA]; Cytochrome P450 2C19 Inducers [MoA]; Cytochrome P450 2C8 Inducers [MoA]; Cytochrome P450 2C8 Inhibitors [MoA]; Cytochrome P450 2C9 Inducers [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 3A Inducers [MoA]; Cytochrome P450 3A Inhibitors [MoA]; P-Glycoprotein Inducers [MoA]; P-Glycoprotein Inhibitors [MoA]; Chloride Channel Activation Potentiators [MoA]

5.2 ATC Code

R07AX30

Digital Content

Create Content with PharmaCompass, ask us